BRPI0520092A2 - derivado de feniloxianilina marcado com halogênio radioativo, e, agente de diagnósitico de doença - Google Patents

derivado de feniloxianilina marcado com halogênio radioativo, e, agente de diagnósitico de doença

Info

Publication number
BRPI0520092A2
BRPI0520092A2 BRPI0520092-0A BRPI0520092A BRPI0520092A2 BR PI0520092 A2 BRPI0520092 A2 BR PI0520092A2 BR PI0520092 A BRPI0520092 A BR PI0520092A BR PI0520092 A2 BRPI0520092 A2 BR PI0520092A2
Authority
BR
Brazil
Prior art keywords
radioactive halogen
pbr
alkoxy group
radioactive
group
Prior art date
Application number
BRPI0520092-0A
Other languages
English (en)
Inventor
Halldin Christar
Kazutoshi Suzuki
Tetsuya Suhara
Ming-Rong Zhang
Atsuro Nakazato
Original Assignee
Taisho Pharmaceutical Co Ltd
Nat Inst Radiolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd, Nat Inst Radiolog filed Critical Taisho Pharmaceutical Co Ltd
Publication of BRPI0520092A2 publication Critical patent/BRPI0520092A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/88—Carboxylic acid amides having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DERIVADO DE FENILOXIAMLINA MARCADO COM HALOGêNIO RADIOATIVO, E, AGENTE DE DIAGNóSTICO DE DOENçA. Derivado de feniloxianilina marcado por halogênio radioativo representado pela seguinte fórmula: em que R^ 1^ representa um grupo como grupo alquila; X^ 1^, X^ 2^, X^ 3^ e X^ 4^ representam, cada um, um átomo de hidrogênio, um grupo alquila, um grupo alcóxi, um grupo alcóxi portando ^ 11^C introduzido no mesmo ou um átomo de halogênio radioativo, desde que pelo menos um entre X^ 1^, X^ 2^, X^ 3^ e X^ 4^ represente um grupo alcóxi portando ^ 11^C introduzido no mesmo ou um átomo de halogênio radioativo; composto este que é útil como um ligante de PBR tendo alta afinidade e alta seletividade. Em medição in vitro de PBR, um ligante de PBR tendo alta afinidade e alta seletividade é marcado com uma espécie nuclear de halogênio radioativo para permitir a medição de PBR in vivo com o uso de meios que incluem não só PET, mas também SPECT. Assim, um composto útil no diagnóstico precoce, prevenção e tratamento de doenças como demência do tipo Alzheimer pode ser obtido.
BRPI0520092-0A 2005-02-28 2005-12-28 derivado de feniloxianilina marcado com halogênio radioativo, e, agente de diagnósitico de doença BRPI0520092A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005052527 2005-02-28
PCT/JP2005/024075 WO2006092902A1 (ja) 2005-02-28 2005-12-28 放射性ハロゲン標識フェニルオキシアニリン誘導体

Publications (1)

Publication Number Publication Date
BRPI0520092A2 true BRPI0520092A2 (pt) 2009-08-18

Family

ID=36940944

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520092-0A BRPI0520092A2 (pt) 2005-02-28 2005-12-28 derivado de feniloxianilina marcado com halogênio radioativo, e, agente de diagnósitico de doença

Country Status (15)

Country Link
US (1) US20090234162A1 (pt)
EP (1) EP1854781A1 (pt)
JP (1) JPWO2006092902A1 (pt)
KR (1) KR20070108883A (pt)
CN (1) CN101133017A (pt)
AU (1) AU2005328464B2 (pt)
BR (1) BRPI0520092A2 (pt)
CA (1) CA2599321A1 (pt)
IL (1) IL185333A0 (pt)
MX (1) MX2007010343A (pt)
NO (1) NO20074897L (pt)
RU (1) RU2425824C2 (pt)
UA (1) UA93870C2 (pt)
WO (1) WO2006092902A1 (pt)
ZA (1) ZA200707226B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563305A (zh) * 2006-12-21 2009-10-21 哈默史密斯网上成像有限公司 放射性标记方法
CA2680762A1 (en) * 2007-03-12 2008-09-25 National Institute Of Radiological Sciences Pet visualization of amyloid-associated neuroinflammation in the brain
EP1997515A1 (en) * 2007-05-30 2008-12-03 Bayer Schering Pharma Aktiengesellschaft Use of radiolabelled phenyloxyaniline derivatives for imaging diseases associated with peripheral benzodiazepin receptor's activation
JP5441060B2 (ja) * 2007-10-31 2014-03-12 独立行政法人理化学研究所 創薬のためのｐｅｔスクリーニング用分子プローブを製造するためのキット
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
GB0904715D0 (en) 2009-03-19 2009-05-06 Ge Healthcare Ltd Aryloxyanilide derivataives
GB0921967D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel Aryloxyanilide Derivatives
JP5422782B1 (ja) * 2012-12-21 2014-02-19 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122361A (en) * 1989-04-17 1992-06-16 Trustees Of The University Of Pennsylvania Dopamine receptor ligands and imaging agents
US5993777A (en) * 1993-05-06 1999-11-30 Research Corporation Technologies, Inc. Benzamide compounds for cancer imaging and therapy
JP4302207B2 (ja) * 1997-08-04 2009-07-22 大正製薬株式会社 アリールオキシアニリン誘導体
DE69809063T2 (de) * 1997-08-04 2003-06-12 Nihon Nohyaku Co., Ltd. Aryloxyanilin-derivate
AU4975600A (en) * 1999-04-26 2000-11-10 Emory University 4-fluoroalkyl-3-halophenyl nortropanes
US6843979B2 (en) * 1999-04-26 2005-01-18 Emory University 4-haloethenylphenyl tropane:serotonin transporter imaging agents
RU2300516C2 (ru) * 1999-11-05 2007-06-10 Эмисфере Текнолоджиз, Инк. Соединения феноксикарбоновой кислоты и композиции для доставки активных веществ
US6870069B2 (en) * 2003-01-10 2005-03-22 National Institute Of Radiological Sciences Phenyloxyaniline derivatives

Also Published As

Publication number Publication date
EP1854781A1 (en) 2007-11-14
CA2599321A1 (en) 2006-09-08
UA93870C2 (ru) 2011-03-25
RU2007135882A (ru) 2009-04-10
AU2005328464B2 (en) 2011-02-24
AU2005328464A1 (en) 2006-09-08
KR20070108883A (ko) 2007-11-13
ZA200707226B (en) 2009-09-30
NO20074897L (no) 2007-11-21
JPWO2006092902A1 (ja) 2008-08-07
WO2006092902A1 (ja) 2006-09-08
CN101133017A (zh) 2008-02-27
MX2007010343A (es) 2008-04-16
RU2425824C2 (ru) 2011-08-10
US20090234162A1 (en) 2009-09-17
IL185333A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
Maeda et al. In vivo positron emission tomographic imaging of glial responses to amyloid-β and tau pathologies in mouse models of Alzheimer's disease and related disorders
ES2395721T3 (es) Derivados de tioflavina y su uso en diagnosis y terapia de la enfermedad de alzheimer
HUP0400253A2 (hu) Szilárd fázisú nukleofil fluorozás
BRPI0617151B8 (pt) composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico
BRPI0507684B8 (pt) agentes de contraste para imagem de perfusão miocárdica
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
NO20091428L (no) Forbindelser og metoder for 18F-merkede midler
Ono et al. 99mTc/Re complexes based on flavone and aurone as SPECT probes for imaging cerebral β-amyloid plaques
EA201100301A1 (ru) Daa-пиридин в качестве лиганда периферического бензодиазепинового рецептора для диагностической визуализации и фармацевтического лечения
BRPI0510487A (pt) agentes de contraste para estudo por imagens de perfusão do miocárdio
NO20074897L (no) Radioaktive halogenmerkede fenyloksyanilinderivater
UY27003A1 (es) Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
DE602004016010D1 (de) Verfahren zur ä11cü-radiomarkierung von phenthiazin und phenothiazinartige verbindungen
AR071054A1 (es) Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa.
ATE529425T1 (de) Verbindungen mit affinität zu amyloid
Gebhardt et al. Dynamic behaviour of selected PET tracers in embryonated chicken eggs
IL175667A (en) Imaging agent which comrises a synthetic caspase-3 inhibitor labeled with an imaging moiety, a radiopharmaceutical composition comprising the same, a kit for the preparation of said composition and a method of diagnosis based thereon
BRPI0917147B8 (pt) composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto
Ono et al. SPECT Imaging Agents for Detecting Cerebral β‐Amyloid Plaques
BRPI0409101A (pt) método para produzir um complexo de gálio radiomarcado
CY1107565T1 (el) Ιμιδαζο-πυριμιδινες και τριαζολο-πιριμιδινες: συνδεσμοι υποδοχεα βανζοδιαζεπινης
SV2009003205A (es) Derivados de silicio para obtencion de imagenes por tomografia de emision de positrones (pet)
NZ591824A (en) Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system
DE60207612D1 (de) Verbindungen zur bilddarstellung der alzheimer-krankenheit
DK1359943T3 (da) Biotinderivater og deres konjugater med chelateringsmidler

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DAS PROCURACOES, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2203 DE 26/03/2013.